Project description:Label free quantititative phosphoproteomics analysis following TiO2 enrichment, nanoscale capillary chromatography and high resolution tandem mass spectrometry.
Project description:Toll/interleukin-1 receptor (TIR) domain proteins are immune signaling components and function as NAD+-cleaving enzymes to activate defense responses. Activation of TIRs represses growth and drives cell death in plants and promotes axon degeneration in animals, but how plant TIRs are repressed remains unclear. Here, we show that TIR NADase activity requires a conserved serine residue spatially close to the catalytic glutamate. The plant Ca2+-dependent protein kinases (CPKs), the mammalian Ca2+/calmodulin-dependent protein kinase II delta (CAMK2D) and TANK binding kinase 1 (TBK1) phosphorylate TIR domains at this conserved serine, which blocks TIR NADase activities and functions and thus maintains growth in plants and suppresses SARM1 TIR signaling in animals, respectively. Our findings define a fundamental molecular mechanism by which phosphorylation at a conserved serine residue blocks TIR signaling to balance growth and defense trade-offs.
Project description:This study aims to investigate the protein expression profiles in a murine model of dextran sulfate sodium (DSS)-induced colitis using advanced Astral-DIA quantitative proteomics technology. A total of 12 colon tissue samples were analyzed, including 6 from healthy control mice and 6 from DSS-treated mice with induced colitis. Experimental Design Species: Mus musculus (C57BL/6 strain). Tissue Source: Colon tissues were dissected, snap-frozen in liquid nitrogen, and homogenized to extract proteins. Groups: Control Group: Healthy mice without intervention. DSS Group: Mice subjected to 2.5% DSS administration for 7 days to induce colitis, validated by histopathological assessment.
Project description:Mutations that increase the protein kinase activity of LRRK2 are one of the most common causes of familial Parkinson's disease. LRRK2 phosphorylates a subset of Rab GTPases within their Switch-II motif, impacting interaction with effectors. We describe and validate a new, multiplex targeted mass spectrometry assay to quantify endogenous levels of LRRK2 phosphorylated Rab substrates (Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43) as well as total levels of Rabs, LRRK2 and phosphorylation of the LRRK2 Ser910 and Ser935 biomarker sites. Exploiting this assay, we quantify for the first time the relative levels of each of the pRab proteins in different cells (mouse embryonic fibroblasts & human neutrophils) and mouse tissues (brain, lung, kidney and spleen). We define how each of the different pRab proteins are impacted by Parkinson’s pathogenic LRRK2[R1441C] and VPS35[D620N] mutations as well as LRRK2 inhibitors. We find that the VPS35[D620N], but not LRRK2[R1441C] mutation, enhances Rab1 phosphorylation in a manner blocked by administration of an LRRK2 inhibitor, providing the first evidence that LRRK2 can phosphorylate Rab1 physiologically. We argue that this targeted mass spectrometry assay can replace immunoblotting approaches currently deployed to assess LRRK2 Rab signalling pathway.
Project description:Toxoplasma gondii is a significant pathogen affecting both humans and animals, with clinical symptoms primarily driven by the uncontrolled proliferation of tachyzoites. In this study, we reveal the essential role and functional plasticity of the PP2A-2 holoenzyme in orchestrating daughter cell emergence during tachyzoite division. The holoenzyme, composed of the regulatory subunit TgPR48 (PP2A-B2), the catalytic subunit PP2A-C2, and the scaffolding subunit PP2A-A2, is critical for successful cell division. Depletion of any of these subunits resulted in severe defects in daughter cell emergence and impaired proper cell separation. Phosphoproteomic analysis following PP2A-C2 depletion identified multiple differentially phosphorylated proteins, including potential regulatory substrates DCS1 and DCS2. However, mutating several phosphorylation sites on DCS1 and DCS2 did not significantly alter their function. Interestingly, depletion of DCS1 or DCS2 disrupted TgPR48 localization, while PR48 overexpression partially rescued defects in DCS2-depleted parasites but not in DCS1-depleted parasites. This suggests that PP2A-2 may compensate through additional, yet unidentified, substrates. Our findings highlight the crucial role of PP2A-2–mediated dephosphorylation in T. gondii tachyzoite division and identify potential molecular targets for therapeutic intervention.
Project description:Liposomal amphotericin B is an important frontline drug for the treatment of visceral leishmaniasis, a neglected disease of poverty. The mechanism of action of amphotericin B (AmB) is thought to involve interaction with ergosterol and other ergostane sterols, resulting in disruption of the integrity and key functions of the plasma membrane. Emergence of clinically refractory isolates of L. donovani and L. infantum is an ongoing issue and knowledge of potential resistance mechanisms can help to alleviate this problem. Here we report the characterisation of four independently selected L. donovani clones that are resistant to AmB. Whole genome sequencing revealed that in three of the moderately resistant clones, resistance was due solely to the deletion of a gene encoding C24-sterol methyltransferase (SMT1). The fourth, hyper-resistant resistant clone (>60-fold) was found to have a 24 bp deletion in both alleles of a gene encoding a putative cytochrome P450 reductase (P450R1). Metabolic profiling indicated these parasites were virtually devoid of ergosterol (0.2% versus 18% of total sterols in wild-type) and had a marked accumulation of 14-methylfecosterol (75% versus 0.1% of total sterols in wild-type) and other 14-alpha methylcholestanes. These are substrates for sterol 14-alpha demethylase (CYP51) suggesting that this enzyme is a bona fide P450R specifically involved in electron transfer from NADPH to CYP51 during catalysis. Deletion of P450R1 in wild-type cells phenocopied the metabolic changes observed in our AmB hyper-resistant clone as well as in CYP51 nulls. Likewise, addition of a wild type P450R1 gene restored sterol profiles to wild type. Our studies indicate that P450R1 is essential for L. donovani amastigote viability, thus loss of this gene is unlikely to be a driver of clinical resistance. Nevertheless, investigating the mechanisms underpinning AmB resistance in these cells provided insights that refine our understanding of the L. donovani sterol biosynthetic pathway.
Project description:Alzheimer's disease (AD) is a progressive neurodegenerative disorder that impairs memory, cognition, behavior, and other cognitive functions. Despite significant advances in understanding its molecular mechanisms, a definitive cure remains elusive. However, some treatments have the potential to slow disease progression if applied before brain damage occurs. Therefore, the identification of reliable biomarkers is critical for early diagnosis of AD and effective intervention. Recent advances in proteomics and the increased accuracy of machine learning algorithms have enhanced biomarker discovery and validation. In this study, we used a newly developed proteomic pipeline to analyse cerebrospinal fluid (CSF) to profile the proteome of AD patients, which included two different subgroups based on their CSF levels of tau. Then, machine learning was used to identify proteins that best classified the two subgroups of AD patients compared to non-AD controls. The resulting model, based on few CSF proteins, demonstrated high accuracy in predicting AD and differentiating patients with elevated or normal CSF tau levels. These protein classifiers, detectable in the preclinical stages of AD, were further validated in silico using larger, publicly available proteomic datasets, confirming their potential as early diagnostic tools.